Mitochondrial-based Therapies Offer New Ways to Tackle Acute and Chronic Conditions

Print Friendly, PDF & Email

Photo courtesy of Cohbar

Photo Courtesy of CohBar, Inc. 

CohBar, Inc. is pioneering mitochondrial-based therapies with a candidate in a Phase Ia/Ib clinical trial as a potential treatment for nonalcoholic steatohepatitis (NASH) and obesity, where top-line results are expected later this year. A potential therapy for acute respiratory distress syndrome (ARDS) also is in preclinical development, along with other candidates that have the potential to enter Phase I trials in 2022.

Click here to read the full article!